FY2029 Earnings Estimate for PRCT Issued By Leerink Partnrs

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Equities researchers at Leerink Partnrs issued their FY2029 EPS estimates for shares of PROCEPT BioRobotics in a research report issued on Tuesday, February 25th. Leerink Partnrs analyst M. Kratky expects that the company will post earnings of $0.48 per share for the year. The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The firm had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million.

A number of other equities analysts have also weighed in on the stock. Morgan Stanley reduced their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research note on Wednesday. Truist Financial restated a “buy” rating and set a $90.00 price objective (down from $105.00) on shares of PROCEPT BioRobotics in a research note on Wednesday. Jefferies Financial Group started coverage on shares of PROCEPT BioRobotics in a report on Thursday, November 14th. They issued a “hold” rating and a $95.00 target price on the stock. Finally, Wells Fargo & Company reissued an “overweight” rating and issued a $112.00 price target on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $94.29.

PROCEPT BioRobotics Price Performance

Shares of PRCT stock opened at $68.11 on Thursday. The firm has a market capitalization of $3.55 billion, a price-to-earnings ratio of -34.93 and a beta of 1.03. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics has a 12-month low of $45.20 and a 12-month high of $103.81. The firm has a fifty day moving average of $75.25 and a 200-day moving average of $79.94.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, EVP Alaleh Nouri sold 28,092 shares of PROCEPT BioRobotics stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the completion of the transaction, the executive vice president now directly owns 52,472 shares in the company, valued at $5,096,605.36. This trade represents a 34.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Reza Zadno sold 26,423 shares of PROCEPT BioRobotics stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $97.22, for a total transaction of $2,568,844.06. Following the transaction, the chief executive officer now owns 152,762 shares of the company’s stock, valued at $14,851,521.64. This represents a 14.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 17.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Raleigh Capital Management Inc. acquired a new position in shares of PROCEPT BioRobotics during the fourth quarter valued at about $32,000. Thematics Asset Management purchased a new position in PROCEPT BioRobotics during the fourth quarter worth about $46,000. Signaturefd LLC boosted its holdings in PROCEPT BioRobotics by 26.7% during the fourth quarter. Signaturefd LLC now owns 689 shares of the company’s stock worth $55,000 after purchasing an additional 145 shares during the last quarter. IFP Advisors Inc purchased a new position in PROCEPT BioRobotics during the fourth quarter worth about $58,000. Finally, Arcadia Investment Management Corp MI purchased a new position in PROCEPT BioRobotics during the fourth quarter worth about $64,000. 89.46% of the stock is currently owned by institutional investors and hedge funds.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).